Difference between revisions of "Wilms tumor"
Jump to navigation
Jump to search
| Line 54: | Line 54: | ||
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | !style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
| − | |[https://www. | + | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17139-0/fulltext de Kraker et al. 2004 (SIOP 93-01)] |
| style="background-color:#1a9851" |Phase III (E) | | style="background-color:#1a9851" |Phase III (E) | ||
|Prolonged chemotherapy | |Prolonged chemotherapy | ||
| style="background-color:#eeee01" |Equivalent EFS | | style="background-color:#eeee01" |Equivalent EFS | ||
| + | |- | ||
| + | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62395-3/fulltext Pritchard-Jones et al. 2015 (SIOP WT 2001)] | ||
| + | | style="background-color:#1a9851" |Phase III (E) | ||
| + | |Dactinomycin, Doxorubicin, Vincristine | ||
| + | | style="background-color:#eeee01" |Non-inferior EFS | ||
|- | |- | ||
|} | |} | ||
| Line 67: | Line 72: | ||
===References=== | ===References=== | ||
| − | # '''SIOP 93-01:''' de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF; SIOP. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004 Oct 2-8;364(9441):1229-35. [https://www. | + | # '''SIOP 93-01:''' de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF; SIOP. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004 Oct 2-8;364(9441):1229-35. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17139-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15464183 PubMed] |
| + | # '''SIOP WT 2001:''' Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1156-64. Epub 2015 Jul 9. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62395-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26164096 PubMed] | ||
[[Category:Wilms' tumor regimens]] | [[Category:Wilms' tumor regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Pediatric cancers]] | [[Category:Pediatric cancers]] | ||
Revision as of 15:08, 16 December 2018
| Section editor | |
|---|---|
 |
Wayne H. Liang, MD, MS Birmingham, AL Twitter: WayneLiangMD |
3 regimens on this page
3 variants on this page
|
All lines of therapy
Dactinomycin monotherapy
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Wolff et al. 1968 | Randomized (E) | Single course of dactinomycin | Seems to have superior RFS |
Preceding treatment
Chemotherapy
- Dactinomycin (Cosmegen) 15 mcg/kg IV once per day on days 1 to 5
6-week cycle for 3 cycles, then 3-month cycle for 4 cycles
References
- Wolff JA, Newton WA Jr, Krivit W, D'Angio GJ. Single versus multiple dose dactinomycin therapy of Wilms's tumor: a controlled co-operative study conducted by the Children's Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A). N Engl J Med. 1968 Aug 8;279(6):290-4. link to original article PubMed
- Update: Wolff JA, D'Angio G, Hartmann J, Krivit W, Newton WA Jr. Long-term evaluation of single versus multiple courses of actinomycin D therapy of Wilms's tumor. N Engl J Med. 1974 Jan 10;290(2):84-6. link to original article contains verified protocol PubMed
Dactinomycin & Vincristine
| back to top |
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| de Kraker et al. 2004 (SIOP 93-01) | Phase III (E) | Prolonged chemotherapy | Equivalent EFS |
| Pritchard-Jones et al. 2015 (SIOP WT 2001) | Phase III (E) | Dactinomycin, Doxorubicin, Vincristine | Non-inferior EFS |
Preceding treatment
Chemotherapy
References
- SIOP 93-01: de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF; SIOP. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004 Oct 2-8;364(9441):1229-35. link to original article PubMed
- SIOP WT 2001: Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1156-64. Epub 2015 Jul 9. link to original article PubMed